Keros Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Keros Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Keros Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$53M, a 34.3% decline year-over-year.
  • Keros Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$182M, a 27.4% decline year-over-year.
  • Keros Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$153M, a 46.2% decline from 2022.
  • Keros Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$105M, a 78.2% decline from 2021.
  • Keros Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58.7M, a 29.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$182M -$53M -$13.5M -34.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$168M -$45.3M -$7.75M -20.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-06
Q1 2024 -$160M -$43.1M -$7.31M -20.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-06
Q4 2023 -$153M -$40.2M -$10.5M -35.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$142M -$39.4M -$15.9M -67.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$127M -$37.5M -$10.2M -37.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-06
Q1 2023 -$116M -$35.8M -$11.6M -48% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-06
Q4 2022 -$105M -$29.7M -$22.8M -328% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$81.9M -$23.5M -$3.21M -15.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$78.7M -$27.3M -$11.6M -74.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-06
Q1 2022 -$67M -$24.2M -$8.3M -52.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-06
Q4 2021 -$58.7M -$6.94M +$3.74M +35% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$62.5M -$20.3M -$8.26M -68.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$54.2M -$15.6M -$4.87M -45.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$49.4M -$15.9M -$3.99M -33.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$45.4M -$10.7M -$7.93M -288% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-09
Q3 2020 -$37.4M -$12M -$8.49M -239% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$28.9M -$10.8M -$7.9M -277% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$21M -$11.9M -$8.71M -274% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$12.3M -$2.75M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$3.55M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$2.85M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$3.18M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.